Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Results from animal studies have suggested that serotonin (5-HT) antagonists acting on the 5-HT3 receptor may have anxiolytic properties. We have assessed whether pretreatment with the 5-HT3 receptor antagonist BRL 46470 (1 mg orally) attenuates the increase in anxiety induced in healthy volunteers by intravenous infusion of m-chlorophenylpiperazine (mCPP: 0.08 mg/kg over 2 min). In this double-blind placebo-controlled crossover study in 12 healthy men who were volunteers, infusion of mCPP caused significant increases in self-ratings for the psychological and physical symptoms of anxiety, for the symptoms of panic attack, and in the plasma levels of cortisol and prolactin, with four subjects (33%) experiencing an mCPP-induced "panic attack." Pretreatment with BRL 46470 did not attenuate any of these mCPP-induced changes. These results do not support suggestions from animal studies that 5-HT3 receptor antagonists can attenuate mCPP-induced anxiety, although it is conceivable that a different dose of BRL 46470 may have been effective.

Type

Journal article

Journal

Biol Psychiatry

Publication Date

01/09/1994

Volume

36

Pages

309 - 316

Keywords

Administration, Oral, Adolescent, Adult, Anti-Anxiety Agents, Anxiety, Brain, Bridged Bicyclo Compounds, Bridged Bicyclo Compounds, Heterocyclic, Cross-Over Studies, Double-Blind Method, Humans, Hydrocortisone, Indoles, Infusions, Intravenous, Male, Middle Aged, Panic, Piperazines, Premedication, Prolactin, Receptors, Serotonin, Serotonin Antagonists, Serotonin Receptor Agonists